Samsung Biopharmaceuticals Holdings Co., Ltd.: The subsidiary Samsung Biopharmaceuticals signed an exclusive supply agreement under the Brazilian government's rare disease treatment program to supply SB12, a biosimilar of eculimab.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.